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Summary
Background Metformin reduces cardiovascular risk in patients with type 2 diabetes seemingly independent of 
lowering blood glucose concentration. We assessed the cardiovascular eﬀ ects of metformin in individuals without 
type 2 diabetes.
Methods We did a single-centre, double-blind, placebo-controlled trial at the Glasgow Clinical Research Facility 
(Glasgow, UK). We enrolled patients taking statins who did not have type 2 diabetes but who did have coronary 
heart disease and large waist circumferences. Participants were randomly assigned (1:1) by computer to either 
metformin (850 mg twice daily) or matching placebo in block sizes of four. Patients, investigators, trial staﬀ , and 
statisticians were masked to treatment allocation. The primary endpoint was progression of mean distal carotid 
intima-media thickness (cIMT) over 18 months in the modiﬁ ed intention-to-treat population. Secondary endpoints 
were changes in carotid plaque score (in six regions), measures of glycaemia (HbA1c, fasting glucose, and insulin 
concentrations, and Homeostasis Model Assessment of Insulin Resistance [HOMA-IR]), and concentrations of 
lipids, high sensitivity C-reactive protein, and tissue plasminogen activator. The trial was registered at ClinicalTrials.
gov, number NCT00723307.
Findings We screened 356 patients, of whom we enrolled 173 (86 in the metformin group, 87 in the placebo group). 
Average age was 63 years. At baseline, mean cIMT was 0·717 mm (SD 0·129) and mean carotid plaque score was 2·43 
(SD 1·55). cIMT progression did not diﬀ er signiﬁ cantly between groups (slope diﬀ erence 0·007 mm per year, 95% CI 
–0·006 to 0·020; p=0·29). Change of carotid plaque score did not diﬀ er signiﬁ cantly between groups (0·01 per year, 
95% CI –0·23 to 0·26; p=0·92). Patients taking metformin had lower HbA1c, insulin, HOMA-IR, and tissue 
plasminogen activator compared with those taking placebo, but there were no signiﬁ cant diﬀ erences for total 
cholesterol, HDL-cholesterol, non-HDL-cholesterol, triglycerides, high sensitivity C-reactive protein, or fasting glucose. 
138 adverse events occurred in 64 patients in the metformin group versus 120 in 60 patients in the placebo group. 
Diarrhoea and nausea or vomiting were more common in the metformin group  than in the placebo group (28 vs 5).
Interpretation Metformin had no eﬀ ect on cIMT and little or no eﬀ ect on several surrogate markers of cardiovascular 
disease in non-diabetic patients with high cardiovascular risk, taking statins. Further evidence is needed before 
metformin can be recommended for cardiovascular beneﬁ t in this population.
Funding Chief Scientist Oﬃ  ce (Scotland).
Introduction
Cardiovascular disease is a leading cause of morbidity 
and mortality. Although type 2 diabetes increases 
cardiovascular risk, people with non-diabetic dysglycaemia 
also have increased risk1 and some researchers regard 
insulin resistance as the most important cardiovascular 
risk factor.2 The proatherogenic phenotype characterising 
dysglycaemia includes dyslipidaemia, vascular dys-
function, inﬂ ammation, and abnormal haemostasis, each 
of which are associated with cardiovascular events.3,4
Metformin—a safe and inexpensive glucose-lowering 
drug—is sometimes used to treat non-diabetic people 
with polycystic ovarian syndrome, for aiding weight 
loss, and for some people with impaired glucose 
tolerance, partly on the basis of its purported 
cardiovascular beneﬁ ts.5–7 Metformin improves 
dyslipidaemia and reduces concentrations of inﬂ am-
matory and haemostatic biomarkers in non-diabetic 
individuals,8,9 suggesting possible cardio vascular 
beneﬁ t. The eﬀ ect of metformin on cardiovascular 
outcomes of patients with type 2 diabetes has been 
studied in two randomised controlled trials. In the 
UKPDS, overweight patients taking metformin had a 
39% lower risk of myocardial infarction over 10 years 
than did patients on conventional dietary therapy, and 
post-trial observational data showed continuing 
beneﬁ t.10,11 In the HOME trial,12 which included 
390 patients with type 2 diabetes on insulin, metformin 
reduced the composite cardiovascular endpoint by 
40%. Metformin treatment also reduces the risk of 
developing type 2 diabetes.13 However, its eﬀ ects on 
cardiovascular endpoints in non-diabetic people 
remain unknown.
We designed the Carotid Atherosclerosis: MEtformin 
for insulin ResistAnce (CAMERA) study to assess the 
eﬀ ect of metformin on progression of mean carotid 
intima-media thickness (cIMT) in non-diabetic 
individuals with coronary heart disease.
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Methods
Study design and participants
CAMERA was a randomised, placebo-controlled, double-
blind trial done at the Glasgow Clinical Research Centre 
(Glasgow, UK). Inclusion criteria were: age 35–75 years, 
proven coronary heart disease (previous acute coronary 
syndrome, coronary artery bypass surgery, or 
angiographically proven coronary heart disease), large 
waist circumference as per International Diabetes 
Foundation criteria (≥94 cm in men, ≥80 cm in women),14 
and prescribed a statin (dose and type were not adjusted15). 
Exclusion criteria were: pregnancy or lactation at 
screening; premenopausal woman not taking adequate 
contraception (daily oral hormonal con traception or 
regular injectable hormonal con traception); type 2 
diabetes or people with either HbA1C of 7·0% 
(53 mmol/mol) or more, or fasting plasma glucose of 
7·0 mmol/L or more at screening; acute coronary 
syndrome within the previous 3 months; New York Heart 
Association functional class 3 or 4 heart failure; un-
controlled angina; hepatic impairment (based on 
assessment of available liver function tests and liver 
imaging by the study physician but not on biochemical 
thresholds); renal impairment (estimated glomerular 
ﬁ ltration rate <45 mL/min per 1·73 m² at screening); 
hypersensitivity to metformin; acute illness (dehydration, 
severe infection, shock, acute cardiac failure); and 
suspected tissue hypoxia. People with HbA1C 6·0–6·9% 
(42–52 mmol/mol) and fasting plasma glucose less than 
7·0 mmol/L at screening had an oral glucose tolerance 
test; those with post-challenge glucose of 11·1 mmol/L or 
more were excluded. The trial was designed before the 
adoption of HbA1c as a diagnostic test for type 2 diabetes.16
All participants provided written informed consent and 
were followed up for 18 months. This study was approved 
by the Medicines and Healthcare Products Regulatory 
Agency and West Glasgow Research Ethics Committee, 
and done in accordance with the principles of the 
Declaration of Helsinki and good clinical practice 
guidelines.
Randomisation and masking
Participants were randomly assigned to metformin or 
placebo (1:1) on the CAMERA website. The randomisation 
sequence was generated independently by computer (by 
the Robertson Centre for Biostatistics) with permuted 
blocks of four without stratiﬁ cation. Patients, investi-
gators, trial staﬀ , and statisticians were masked to 
treatment allocation. 
Procedures
Participants were advised to take one study tablet (850 mg 
metformin or matching placebo) daily for 1 week before 
titrating up to 2 tablets daily (one with the morning meal, 
one with the evening meal). Participants unable or 
unwilling to take the medication twice daily could take 
one tablet daily from any point. Masked study medication 
was supplied in numbered bottles and compliance 
(deﬁ ned as taking >80% of study medication during the 
trial) was assessed by tablet count. Study medication was 
reduced to one tablet daily if estimated glomerular 
ﬁ ltration rate fell below 45 mL/min per 1·73 m², and 
stopped below 30 mL/min per 1·73 m².
Metformin group 
(n=86)
Placebo group 
(n=87)
Age (years) 63 (8) 64 (8)
Men 70 (81%) 63 (72%)
Smoking history
Current 18 (21%) 17 (20%)
Former 42 (49%) 50 (57%)
Never 26 (30%) 20 (23%)
Blood pressure (mm Hg) 142/80 (21/11) 139/79 (21/12)
Heart rate (beats per min) 63 (11) 65 (10)
Bodyweight (kg) 87·8 (14·1) 86·8 (15·0)
Body-mass index (kg/m²) 30·2 (4·1) 30·5 (4·4)
Waist circumference (cm) 105 (10) 104 (10)
Hip circumference (cm) 108 (8) 108 (8)
Body fat (kg) 28·2 (7·5) 29·1 (7·5)
(Continues on next page)
Figure 1: Trial proﬁ le
71 attended 6 month visit
69 attended 12 month visit
74 attended 18 month visit
75 attended at least one 12 month or 18 month 
visit for carotid intima-media thickness scan
Reasons for not attending 18 month visit 
5 unwilling to continue
5 lost to follow-up
1 died
1 other
20 discontinued intervention
86 allocated to and received metformin 87 allocated to and received placebo
173 randomly assigned
11 excluded from 
primary outcome 
analysis
4 excluded from 
primary outcome 
analysis
356 patients assessed for
 eligibility
81 attended 6 month visit
79 attended 12 month visit
83 attended 18 month visit
83 attended at least one 12 month or 18 month 
visit for carotid intima-media thickness scan
Reasons for not attending 18 month visit 
3 unwilling to continue
1 lost to follow-up
12 discontinued intervention
183 excluded
182 did not meet inclusion criteria
144 excluded by telephone screening
38 excluded after screening visit
1 declined to participate
75 included in primary outcome analysis 83 included in primary outcome analysis
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For assessment of mean cIMT, carotid artery scans 
were done at baseline, 12 months, and 18 months. The 
imaging protocol consisted of B-mode ultrasound image 
acquisition of the right and left far walls of the distal 
10 mm of the common carotid arteries, using an Acuson 
Sequoia C512 (Siemens Medical Solutions; Erlangen, 
Germany) with an L8 5–12 MHz linear array broadband 
transducer, and electrocardiogram gating.17 All images 
were obtained from a single ultrasound machine by one 
doctor (DP). Participants were positioned recumbent 
with the head tilted 10° to the contralateral side. On each 
side of the neck, three digital clips were recorded from 
lateral, posterolateral, and anterolateral angles, each clip 
including roughly three QRS complexes. Depending on 
image quality, up to 18 cIMT images (in end-diastolic 
frame) were available from each visit for analysis of 
mean cIMT. Mean left-side and right-side cIMT were 
calculated separately and averaged to give the overall 
mean cIMT. Participants in whom only one side could 
be assessed at baseline had the same side analysed 
throughout. Images were analysed when all study visits 
had been completed by a single researcher using 
semiautomated artery measurement software18 or a 
combination of semiautomated and manual approaches 
depending on image quality. Pretrial intra-individual 
cIMT reproducibility was 7%.
Carotid plaque score—a value of 0–6 depending on 
plaque presence in six regions—was assessed by 
transverse and longitudinal transducer positioning. 
Presence of plaque was assessed in three regions for 
both left and right carotid arteries (ie, six regions): distal 
10 mm of the common carotid artery, carotid bulb (from 
the widening of the common carotid artery to the ﬂ ow 
divider), and proximal 10 mm of the internal carotid 
artery (distal from the ﬂ ow divider). Plaque was deﬁ ned 
as cIMT of 1·5 mm or more, or 0·5 mm or more focal 
encroachment into the arterial lumen. Plaques in the 
entire common carotid artery and internal carotid artery 
were also recorded for a sensitivity analysis to avoid any 
eﬀ ect of variations in the selection of the 10 mm 
boundaries. Other plaque surrogate markers (carotid 
plaque area and carotid plaque volume) have been 
proposed;19 however, we did not use them because of 
concern about potential subjectivity of carotid plaque 
area and the requirement for experience in operating 
specialised equipment to assess carotid plaque volume.
Laboratory assessments measured at every visit 
included renal and liver function tests and—at every 
6 month visit—fasting plasma glucose, HbA1c, fasting 
lipid proﬁ le, high sensitivity C-reactive protein, fasting 
insulin, vitamin B12, tissue plasminogen activator, and 
high sensitivity troponin T. With the exception of insulin, 
vitamin B12, tissue plasminogen activator, and high 
sensitivity troponin T, all biochemical and haematology 
analyses were done at Gartnavel General Hospital, 
Glasgow, UK, with strict quality control procedures and 
where all assays (Abbott Diagnostics, North Chicago, IL) 
performed acceptably according to UK National External 
Quality Assessment Service, our external quality 
assurance scheme. Vitamin B12 and high sensitivity 
troponin T were analysed from stored plasma samples 
with an automated clinically validated analyser (Roche 
Diagnostics; Burgess Hill, UK) and manufacturer 
standards and quality control material; the low control 
coeﬃ  cient of variation was 8·1% for vitamin B12 and 
Metformin group 
(n=86)
Placebo group 
(n=87)
(Continued from previous page)
Medical history
Essential hypertension 35 (41%) 38 (44%)
Myocardial infarction 46 (53%) 38 (44%)
Coronary stent 29 (34%) 29 (33%)
Coronary artery bypass graft 23 (27%) 26 (30%)
Chronic heart failure (NYHA I or II) 9 (10%) 7 (8%)
Stroke 1 (1%) 3 (3%)
Biochemistry (fasting)
Plasma glucose (mmol/L) 5·4 (0·6) 5·3 (0·5)
Insulin (pmol/L)* 60·6 (9·6) 62·4 (10·2)
HOMA-IR* 2·38 (1·67) 2·42 (1·73)
HbA1c (%) 5·68 (0·32) 5·63 (0·31)
HbA1c (mmol/mol) 38·7 (3·6) 38·2 (3·3)
High sensitivity C-reactive protein (mg/L)* 1·8 (2·9) 1·9 (3·1)
Total cholesterol (mmol/L) 4·2 (0·8) 4·3 (0·9)
HDL-cholesterol (mmol/L) 1·2 (0·3) 1·2 (0·3)
Non-HDL-cholesterol (mmol/L) 3·0 (0·8) 3·1 (0·9)
Triglycerides (mmol/L)* 1·5 (1·7) 1·5 (1·6)
Estimated glomerular ﬁ ltration rate (mL/min per 1·73 m²) 85 (16) 81 (17)
Alanine aminotransferase (U/L) 29·0 (17·5) 27·6 (12·4)
γ-glutamyltransferase (U/L)* 39·5 (2·0) 36·3 (2·1)
Vitamin B12 (pmol/L) 272 (115) 293 (132)
High sensitivity troponin T (pg/mL) 10·5 (4·6) 10·3 (5·7)
Tissue plasminogen activator (ng/mL) 9·4 (4·3) 9·6 (3·9)
Concomitant drugs
Statin 86 (100%) 87 (100%)
Duration of statin treatment (years) 6·4 (3·7) 6·6 (4·2)
Duration of intensive statin treatment (years)† 4·4 (3·0) 4·5 (3·4)
Duration of moderate-dose statin treatment (years)‡ 2·1 (3·8) 2·1 (3·7)
ACE inhibitor or angiotensin 2 receptor blocker 58 (67%) 45 (52%)
Calcium channel blockers 23 (27%) 26 (30%)
β blockers 56 (65%) 52 (60%)
Diuretics 13 (15%) 17 (20%)
Nitrates 50 (58%) 50 (57%)
Carotid measurements
Carotid intima-media thickness (mm) 0·718 (0·128) 0·716 (0·131)
Carotid plaque score (out of six)§ 2·38 (1·61) 2·47 (1·49)
Data are mean (SD) or n (%) unless stated otherwise. NYHA=New York Heart Association. HOMA-IR=homoeostatic 
model assessment insulin resistance. *Geometric mean (SD). †Lovastatin ≥80 mg, atorvastatin ≥20 mg, simvastatin 
≥40 mg, or any dose of rosuvastatin daily. ‡All doses lower than intense doses of lovastatin, atorvastatin, simvastatin, 
or any dose of pravastatin or ﬂ uvastatin daily. §In the carotid bulb, distal 10 mm of the common carotid artery, and 
proximal 10 mm of the internal carotid artery. 
Table 1: Baseline characteristics
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8·3% for high sensitivity troponin T and high control 
coeﬃ  cient of variation was 10·4% for vitamin B12 and 
5·7% for high sensitivity troponin T. Concentrations for 
insulin and tissue plasminogen activator were also 
measured from stored samples with commercial ELISAs 
(Mercodia, Diagenics Bletchley, UK; and Stago, Theale, 
UK). Intra-assay coeﬃ  cient of variation was 5·5% for 
insulin and 8·4% for tissue plasminogen activator, and 
interassay coeﬃ  cient of variation was 9·7% for insulin 
and 6·2% for tissue plasminogen activator. We calculated 
homoeostasis model assessment of insulin resistance 
(HOMA-IR; fasting plasma glucose [mmol/L]×fasting 
insulin [mU/L])/22·5) and estimated glomerular 
ﬁ ltration rate (with abbreviated Modiﬁ cation of Diet in 
Renal Disease equation20).
Vital signs (blood pressure, pulse, bodyweight, body fat 
by bio-impedance with a Tanita BIA body fat analyser 
[Tanita Corporation, Tokyo, Japan]), waist circumference 
(measured midway between lowest rib and iliac crest), 
and hip circumference (measured around widest part of 
the buttocks) were measured at each visit. Participants 
were asked about adverse events and serious adverse 
events at each visit. Serious adverse events were recorded 
from paper and electronic hospital records but were not 
independently reviewed.
The primary endpoint was progression of mean distal 
common carotid artery cIMT at 18 months. Secondary 
endpoints were progression of carotid plaque score and 
change in HOMA-IR, HbA1C, total cholesterol, HDL-
cholesterol, non-HDL-cholesterol, triglycerides, tissue 
plasminogen activator, and high sensitivity C-reactive 
protein. Additional (not prespeciﬁ ed) endpoints were 
changes of adiposity (bodyweight, body fat, body-mass 
index (BMI), and waist circumference), vitamin B12 
con centrations, high sensitivity troponin T con-
centrations, and surrogate markers of liver fat—ie, γ 
glutamyl transferase and alanine aminotransferase con-
centrations.
Statistical analysis
Metformin reduced cIMT by 0·032 mm at 12 months in 
a single-centre randomised trial of non-diabetic 
participants (n=60).21 In the single-centre ARBITER trial 
(n=161),22 cIMT decreased by 0·059 mm in 12 months in 
patients taking atorvastatin 80 mg compared with those 
taking pravastatin 40 mg. Our sample size calculations 
suggested that 180 participants completing the trial 
would be needed to detect a diﬀ erence of 0·021 mm 
(SD 0·050 mm) between groups for cIMT progression 
with 80% power at 18 months. This estimate was based 
on two cIMT readings per participant whereas our study 
included three. We initially intended to follow up 
participants for 24 months but this was reduced to 
18 months to enable completion within the time available. 
This change occurred in June 2010, when 115 participants 
had been randomly assigned to treatment but none had 
yet completed 18 months of follow-up.
Non-normally distributed variables were log-
transformed with data presented as geometric means. 
We used repeated measures regression models to assess 
progression of mean cIMT and progression of carotid 
plaque score. These models allowed for participant-
speciﬁ c random intercepts and random slopes. We 
estimated the rate of change (slope) for each treatment 
group and the diﬀ erence in these slopes. We also 
adjusted the models for pre-deﬁ ned baseline 
cardiovascular risk factors (age, sex, smoking status, 
systolic blood pressure, diastolic blood pressure, HDL-
cholesterol, LDL-cholesterol, and estimated glomerular 
ﬁ ltration rate). We did sensitivity analyses for 
progression of mean cIMT for right and left cIMT 
separately; an analysis based on a minimum number of 
cIMT values per participant per visit (when a participant 
had 5–9 measurements per side and when average 
values could be calculated for both sides); an analysis of 
only those participants who completed the study, did 
not reduce the dose, and took more than 80% of study 
medication; and a carotid plaque score analysis of the 
carotid bulb and entire internal carotid artery and 
common carotid artery.
All analyses were done for the modiﬁ ed intention-to-
treat population (had baseline and at least one later cIMT 
or plaque measurement) apart from a pre-planned per-
protocol analysis, which was done for the primary 
outcome including only patients with no major or minor 
protocol deviations. Major protocol deviations included 
errors in the recording of informed consent, failure to 
comply with inclusion or exclusion criteria, and failure to 
amend study drug prescription based on biochemical 
data. Minor protocol deviations included compliance less 
than 50%, failure to attend all visits, failure to record 
study measurements, and stopping study drug before the 
end of the study. We did analyses for the primary 
outcome at 18 months comparing subgroups of tertiles 
for cIMT, fasting insulin, HbA1c, BMI, and non-HDL-
cholesterol at baseline plus sex.
Metformin group Placebo group
Baseline 0·712 (0·126) 0·715 (0·131)
12 months 0·725 (0·127) 0·734 (0·135)
18 months 0·747 (0·142) 0·739 (0·131)
Unadjusted analysis
Slope (95% CI; mm per year) 0·023 (0·014 to 0·032) 0·016 (0·007 to 0·025)
Diﬀ erence in slope (95% CI; mm per year) 0·007 (–0·006 to 0·020); p=0·29 ··
Adjusted analysis*
Slope (95% CI; mm per year) 0·024 (0·014 to 0·033) 0·017 (0·008 to 0·026)
Diﬀ erence in slope (95% CI; mm per year) 0·007 (–0·006 to 0·020); p=0·29 ··
Data are mean (SD) unless otherwise stated. Analyses are for modiﬁ ed intention-to-treat analyses of participants with 
at least one measurement after baseline. Figure 1 shows number of patients attending the relevant visits. *Adjusted 
for age, sex, smoking status, systolic and diastolic blood pressure, HDL-cholesterol, LDL-cholesterol, and estimated 
glomerular ﬁ ltration rate. 
Table 2: Repeated measures analysis of mean carotid intima-media thickness
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Other secondary endpoints and additional endpoints 
were analysed with repeated measures models that 
allowed for random intercepts only and assumed a 
general covariance structure; the visit was ﬁ tted as a 
ﬁ xed categorical variable. Treatment-by-visit interactions 
were evaluated to assess whether overall treatment 
eﬀ ects or treatment eﬀ ect by visit were appropriate 
analyses. Analyses were done with SAS (version 9.3). 
p values were two-sided and 0·05 was the threshold for 
statistical signiﬁ cance.
This trial is registered with ClinicalTrials.gov, number 
NCT00723307.
Role of the funding source
The sponsors had no role in study design, data collection, 
analysis, or interpretation, or writing of the report. DP, 
SML, IF, and NS had access to the raw data. The 
corresponding author had full access to all of the data 
and the ﬁ nal responsibility to submit for publication.
Results
We identiﬁ ed roughly 3000 potential participants from 
electronic searches of Glasgow general practice 
databases, supplemented by patients from hospital 
cardiology clinics. Of those invited, 805 replied and 
356 were screened. 173 were enrolled and randomly 
assigned (86 to metformin, 87 to placebo; ﬁ gure 1). Trial 
visits were done between 2009 and 2012. Baseline 
characteristics did not diﬀ er substantially between 
treatment groups (table 1). Average age was 63 years, 
mean cIMT was 0·717mm (SD 0·129), and mean carotid 
plaque score was 2·43 (SD 1·55). Of the patients for 
whom complete data were available based on drug 
return, 64 of 82 (78%) assigned to metformin and 68 of 
85 (80%) assigned to placebo were compliant. More 
participants taking metformin (n=19) than placebo 
(n=10) reduced to one tablet daily. 12 participants 
assigned to metformin and four assigned to placebo did 
not attend the ﬁ nal visit. Those participants lost to follow-
up (n=6) could not be reached by post or telephone. 
However, according to electronic hospital records, none 
had a serious adverse event during follow-up. During 
follow-up, four participants stopped statin treatment 
Metformin group Placebo group
Carotid bulb, distal 10 mm of common carotid artery, and proximal 10 mm of internal carotid artery
Baseline 2·33 (1·60) 2·50 (1·52)
12 months 2·29 (1·61) 2·63 (1·44)
18 months 2·42 (1·57) 2·55 (1·41)
Unadjusted analysis
Slope (95% CI; points per year) 0·05 (–0·12 to 0·23) 0·04 (–0·13 to 0·21)
Diﬀ erence in slope (95% CI; points per year) 0·01 (–0·23 to 0·26); p=0·92 ··
Adjusted analysis*
Slope (95% CI; points per year) 0·03 (–0·14 to 0·21) 0·05 (–0·12 to 0·22)
Diﬀ erence in slope (95% CI; points per year) –0·02 (–0·26 to 0·23); p=0·89
Carotid bulb, entire common carotid artery, and entire internal carotid artery†
Baseline 2·51 (1·72) 2·61 (1·63)
12 months 2·49 (1·72) 2·79 (1·55)
18 months 2·66 (1·68) 2·82 (1·59)
Unadjusted analysis
Slope (95% CI; points per year) 0·09 (–0·05 to 0·24) 0·14 (0·00 to 0·27)
Diﬀ erence in slope (95% CI; points per year) –0·04 (–0·24 to 0·16); p=0·68 ··
Adjusted analysis*
Slope (95% CI; points per year) 0·08 (–0·07 to 0·22) 0·15 (0·01 to 0·29)
Diﬀ erence in slope (95% CI; points per year) –0·07 (–0·28 to 0·13); p=0·48 ··
Data are mean (SD) unless otherwise stated. Analyses are for modiﬁ ed intention-to-treat analyses of participants with at 
least one measurement after baseline; baseline data missing for one patient in placebo group, therefore not analysed. 
Figure 1 shows number of patients attending the relevant visits. *Adjusted for age, sex, smoking status, systolic and 
diastolic blood pressure, HDL-cholesterol, LDL-cholesterol, and estimated glomerular ﬁ ltration rate. †Sensitivity analysis.
Table 3: Repeated measures analysis of carotid plaque score
Figure 2: Progression in mean cIMT (A), carotid plaque score (B), and bodyweight (C)
Error bars are 95% CIs. cIMT=carotid intima-media thickness.
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(three taking metformin, one taking placebo), while 
estimated glomerular ﬁ ltration rate fell to 30–44 mL/min 
per 1·73m² in ﬁ ve participants (two taking metformin, 
three taking placebo) but did not fall lower than 
30 mL/min/ per 1·73m² in any participants.
Over 18 months, mean cIMT increased signiﬁ cantly in 
both groups (0·024 mm per year [95% CI 0·014 to 0·033] 
for metformin, 0·017mm per year [95% CI 0·008 to 
0·026] for placebo). Rates of cIMT progression in the 
metformin and placebo groups did not diﬀ er signiﬁ cantly 
(diﬀ erence in slope 0·007 mm per year, 95% CI –0·006 
to 0·020; p=0·29; table 2, ﬁ gure 2A). This null cIMT 
ﬁ nding was consistent in all sensitivity analyses (data 
not shown), in the per-protocol population (n=140; 
diﬀ erence in slope 0·008 mm per year, 95% CI –0·005 
to 0·022; p=0·23), and when restricted to participants 
ﬁ ve or more images analysed from each side (data not 
shown). For 101 participants who completed the trial 
without reducing dose and who were compliant with 
study drug (45 in the metformin group and 56 in the 
placebo group), results were also much the same 
(diﬀ erence in slope 0·014 mm per year, 95% CI –0·003 
to 0·031; p=0·11). Analyses using thirds of baseline 
cIMT and thirds of selected baseline variables did not 
identify beneﬁ t in any subgroups (appendix). Similarly, 
there was no diﬀ erence according to sex. Scan 
reproducibility, assessed as SD for change in cIMT in 
the placebo group, was 0·046 mm at 12 months and 
0·059 mm at 18 months.
Change in carotid plaque score in the carotid bulb, 
distal 10 mm of the common carotid artery, and proximal 
10 mm of the internal carotid artery combined did not 
diﬀ er between groups (0·01 per year, 95% CI –0·23 to 
0·26; p=0·92; table 3, ﬁ gure 2B). In the sensitivity 
analysis of carotid plaque score in the carotid bulb, entire 
common carotid artery, and internal carotid artery, 
treatment groups did not diﬀ er signiﬁ cantly (table 3).
HbA1c, log fasting insulin concentration, log HOMA-
IR, and tissue plasminogen activator were reduced in the 
metformin group compared with placebo, whereas we 
detected no signiﬁ cant diﬀ erence for total cholesterol, 
HDL-cholesterol, non-HDL-cholesterol, fasting plasma 
glucose, triglycerides, and high sensitivity C-reactive 
protein (table 4).
Metformin signiﬁ cantly reduced all measures of 
adiposity (bodyweight, body fat, BMI, waist circumference 
compared with placebo at 18 months (p<0·0001 for all). 
Mean weight loss in the metformin group was 3·2 kg 
(SD 4·2) versus 0·0 kg (SD 3·8) in the placebo group at 
18 months (ﬁ gure 2C, appendix). Metformin also led to a 
progressive fall of vitamin B12 concentration (–62 pmol/L, 
95% CI –89 to –35; p<0·0001) by 18 months. γ glu-
tamyltransferase concentration fell in patients taking 
metformin compared with those taking placebo 
(p=0·0002) but high sensitivity troponin T and alanine 
aminotransferase concentrations did not change 
signiﬁ cantly (appendix).
We recorded 258 adverse events: 138 in 64 participants 
assigned to metformin and 120 in 60 participants 
assigned to placebo (table 5, appendix). More patients 
Metformin group 
(mean change; SD)
Placebo group 
(mean change; SD)
Treatment eﬀ ect 
(metformin–placebo)
pinteraction
Eﬀ ect (95% CI)* p value
HbA1c (%)
6 months –0·12 (0·23) 0·04 (0·16) –0·13 (–0·18 to –0·07) <0·0001 0·45
12 months –0·11 (0·19) 0·03 (0·17) ··
18 months –0·14 (0·25) 0·00 (0·26) ··
HbA1c (mmol/mol)
6 months –1·3 (2·6) 0·4 (1·8) –1·4 (–2·0 to –0·8) <0·0001 0·62
12 months –1·2 (2·1) 0·3 (1·8) ··
18 months –1·3 (2·6) 0·1 (2·7) ··
Insulin (log; pmol/L)
6 months –0·16 (0·37) 0·01 (0·51) –0·19 (–0·33 to –0·06) 0·0047 0·89
12 months –0·11 (0·48) 0·09 (0·52) ··
18 months –0·06 (0·59) 0·10 (0·55) ··
HOMA-IR (log)
6 months –0·19 (0·42) –0·01 (0·54) –0·23 (–0·37 to –0·08) 0·0025 0·78
12 months –0·15 (0·50) 0·10 (0·56) ··
18 months –0·08 (0·64) 0·12 (0·61) ··
Glucose (mmol/L)
6 months –0·14 (0·60) –0·01 (0·46) –0·14 (–0·29 to 0·01) 0·064 0·11
12 months –0·08 (0·52) 0·04 (0·52) ··
18 months –0·11 (0·66) 0·17 (0·74) ··
Total cholesterol (mmol/L)
6 months –0·07 (0·81) –0·01 (0·7) –0·03 (–0·25 to 0·18) 0·78 0·81
12 months –0·09 (0·80) –0·08 (0·90) ··
18 months 0·08 (0·85) 0·03 (0·92) ··
HDL-cholesterol (mmol/L)
6 months 0·04 (0·16) 0·02 (0·13) 0·04 (–0·01 to 0·08) 0·095 0·73
12 months 0·05 (0·19) 0·01 (0·13) ··
18 months 0·06 (0·18) 0·02 (0·19) ··
Non-HDL-cholesterol (mmol/L)
6 months –0·12 (0·76) –0·03 (0·69) –0·07 (–0·28 to 0·14) 0·53 0·86
12 months –0·14 (0·76) –0·08 (0·89) ··
18 months 0·02 (0·81) 0·01 (0·93) ··
Triglycerides (log; mmol/L)
6 months –0·10 (0·37) 0·00 (0·31) –0·08 (–0·16 to 0·00) 0·054 0·68
12 months –0·11 (0·40) –0·02 (0·34) ··
18 months –0·07 (0·37) –0·03 (0·40) ··
High-sensitivity C-reactive protein (log; mg/L)
6 months –0·14 (1·00) 0·05 (0·79) –0·19 (–0·39 to 0·00) 0·054 0·84
12 months –0·20 (1·00) –0·02 (0·81) ··
18 months –0·23 (0·73) 0·01 (0·97) ··
Tissue plasminogen activator (ng/mL)
6 months –0·93 (2·91) –0·38 (2·29) –0·77 (–1·46 to –0·08) 0·029 0·21
12 months –1·00 (2·92) 0·21 (2·72) ··
18 months –0·90 (3·60) –0·57 (2·91) ··
*Overall treatment eﬀ ects given that treatment eﬀ ect by time was not signiﬁ cant; modiﬁ ed intention-to-treat analysis for 
participants with at least one measurement after baseline. Figure 1 shows number of patients attending the relevant visits. 
Table 4: Eﬀ ect of metformin treatment on secondary endpoints
See Online for appendix
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assigned to metformin developed diarrhoea and nausea 
or vomiting than those assigned to placebo (28 vs 5). 41 
serious adverse events occurred, 14 in 11 participants 
assigned to metformin and 27 in 18 participants assigned 
to placebo. Few participants had cardiovascular events 
(n=10), were diagnosed with cancer (n=5), or developed 
type 2 diabetes (n=8). One participant had an out-of-
hospital cardiac arrest and died from presumed 
cardiovascular causes in the ﬁ rst few months of follow-
up and therefore no data were available for analyses of 
the primary and secondary endpoints.
Discussion
Metformin—a drug already used for patients without 
type 2 diabetes—did not reduce progression of mean 
cIMT or carotid plaque score at 18 months in statin-
treated non-diabetic participants with established 
coronary heart disease and large waist circumferences. 
Metformin generated expected reductions in markers of 
diabetes risk together with notable reductions in 
measures of adiposity. Gastrointestinal adverse events 
were common in patients taking metformin.
The results of twwo previous randomised trials—
UKPDS10 and HOME12—suggest that metformin reduces 
cardiovascular risk for patients with type 2 diabetes 
(panel). In UKPDS, the cardiovascular beneﬁ t was 
greater than expected for the diﬀ erences in glycaemic 
control achieved, suggesting that metformin might 
reduce cardiovascular risk for non-diabetic individuals by 
mechanisms independent of glucose-lowering. However, 
less than 2% of participants in UKPDS and 32% in 
HOME were treated with statins. All participants in 
CAMERA were taking statins, which might have limited 
the ability of metformin to show a reduction in cIMT. 
Similarly, although small randomised trials of metformin 
have shown reductions of total cholesterol and LDL-
cholesterol8 in people who did not have diabetes, 
participants in CAMERA had no improvement for these 
predictors. A meta-analysis has also cast doubt on 
metformin’s purported cardiovascular beneﬁ ts.24
Metformin can modestly reduce weight.13 In CAMERA, 
participants who were selected partly on the basis of 
large waist circumference had sustained and progressive 
reductions for all measures of adiposity, similar to that 
achieved by weight loss drugs,25 even in this non-diabetic 
group. Metformin can also reduce hepatic steatosis and 
biochemical markers of liver fat;26 we recorded a 
reduction in γ glutamultransferase but not alanine 
aminotranferase concentrations. As in previous studies,27 
a moderate fall in vitamin B12 concentrations occurred 
in the metformin group. Tissue plasminogen activator 
was also lower with metformin than with placebo, 
consistent with previous studies,8 suggesting that its 
purported cardiovascular beneﬁ t could partially be a 
result of a reduction in prothrombotic potential. 
Unexpectedly, high sensitivity troponin T concentrations 
were higher in the metformin group than in the placebo 
group (though not signiﬁ cantly) in the absence of change 
of renal function. This ﬁ nding should be studied further.
CAMERA had several strengths, including its 
randomised placebo-controlled double-blind design; 
inclusion of patients with high cardiovascular risk, all 
taking statins as per best practice; ultrasound scans were 
analysed with semiautomated software and yearly cIMT 
progression rates were entirely consistent with large 
pooled studies,28 suggesting that our method was robust; 
Panel: Research in context
Systematic review
Treatment with metformin was shown to reduce cardiovascular events in patients with 
type 2 diabetes by the initial 10 year follow-up of UKPDS,10 with continued beneﬁ t shown in 
a subsequent analysis of long-term follow-up over 25 years.11 Systematic reviews and 
meta-analyses of the cardiovascular eﬀ ects of metformin have produced mixed results 
depending on the inclusion criteria used. For example, a systematic review23 published in 
2008 found that metformin treatment reduced cardiovascular mortality by 26% in an 
analysis of 11 385 patients with type 2 diabetes from six trials. By contrast, a meta-analysis24 
published in 2012 with 13 110 participants with type 2 diabetes from ten trials found no 
change in cardiovascular mortality. Given that a generic form of metformin is available and 
has also been shown to reduce the risk of developing type 2 diabetes,13 there is interest in its 
cardiovascular eﬀ ects for individuals at high cardiovascular risk but without type 2 diabetes.
Interpretation
In the placebo-controlled CAMERA study, we evaluated the eﬀ ect of metformin treatment 
on the progression of carotid intima-media thickness, carotid plaque score, and other 
surrogate markers of cardiovascular disease and type 2 diabetes in 173 participants without 
diabetes but with established coronary heart disease already taking statins. Over 18 months, 
neither carotid intima-media thickness nor carotid plaque score improved for patients 
taking metformin. However, metformin did lead to a signiﬁ cant reduction of weight 
together with improvements in other risk factors for development of type 2 diabetes. Major 
cardiovascular outcome trials are needed to conclusively assess metformin’s cardiovascular 
eﬀ ects in people without type 2 diabetes—such trials are underway at present.
Metformin 
group 
(n=86)
Placebo 
group 
(n=87)
Diarrhoea 18 (21%) 4 (5%)
Nausea or vomiting 10 (12%) 1 (1%)
Newly diagnosed neoplasm 1 (1%) 4 (5%)
New-onset diabetes* 2 (2%) 6 (7%)
Non-fatal myocardial infarction 0 (0%) 4 (5%)
Unstable angina 0 (0%) 1 (1%)
Coronary stent 2 (2%) 5 (6%)
Non-fatal stroke 1 (1%) 0 (0%)
Cardiovascular death 1 (1%) 0 (0%)
Composite cardiovascular disease event† 4 (5%) 6 (7%)
Data are number of patients (%). The appendix shows a full list of adverse and 
serious adverse events. *HbA1c ≥6·5% (≥48 mmol/mol ) at any post-baseline visit 
or fasting plasma glucose ≥7·0 mmol/L from at least two post-baseline visits 
(three patients had baseline HbA1c ≥6·5% and all subsequent values were <6·5% in 
these patients). †Non-fatal myocardial infarction, non-fatal stroke, coronary 
revascularisation, unstable angina, or cardiovascular death. 
Table 5: Important adverse and serious adverse events
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and we used metformin doses commonly used to treat 
type 2 diabetes, although some participants did reduce 
their dose. Potential weaknesses include use of cIMT—a 
surrogate marker albeit approved by the US Food and 
Drug Administration—as the primary endpoint; some 
drugs have reduced cIMT progression but not improved 
cardiovascular outcomes in large trials29,30 whereas others 
have shown improvements,31,32 and the relationship 
between cIMT progression and cardiovascular events in 
epidemiological studies has been questioned.33 In 
addition, fewer participants than needed completed the 
trial (158 completed vs 180 needed according to our 
sample size calculation), although this calculation was 
based on two carotid ultrasound scans per participant, 
rather than three. Participants were followed up for 
18 months rather than 24 months, although previous 
cIMT studies22,34,35 have shown treatment eﬀ ects over even 
shorter periods. Substantially larger multicentre 
multinational cIMT trials have been done36 but CAMERA 
is similar in size to other single-centre cIMT trials22 and 
beneﬁ ted from a single sonographer and a single scan 
reader throughout. The number of participants who 
discontinued or reduced treatment, together with the use 
of several statistical tests, might have reduced our ability 
to detect meaningful eﬀ ects.
GLINT (ISRCTN34875079), with a feasibility phase 
commencing in 2013, is a double-blind randomised trail 
planned to assign roughly 12 000 people with non-diabetic 
hyperglycaemia and increased cardiovascular risk to 
metformin or placebo for 5 years with a cardiovascular 
primary outcome. Metformin’s eﬀ ect on cardiovascular 
surrogate markers is also being tested in other trials such 
as REMOVAL (assessing change of cIMT over 3 years in 
patients with type 1 diabetes; NCT01483560) and GIPS-III 
(assessing change in left ventricular ejection fraction for 
4 months after acute myocardial infarction in non-diabetic 
patients; NCT01217307).37
Further evidence is needed from large trials of 
cardiovascular outcomes before metformin can be 
recommended for cardiovascular beneﬁ t for non-diabetic 
patients with high cardiovascular risk who are being 
treated with statins.
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